VEGFA and neoplasm: We have found a series of molecules, called ESSOs (named after the researchers’ initials), that have been shown, upon validation, to have anti-angiogenic activity ex vivo and in vivo and to decrease tumour growth in xenografts, through a change in VEGF-A splicing.